Abo Bibliothek: Guest
International Journal of Medicinal Mushrooms

Erscheint 12 Ausgaben pro Jahr

ISSN Druckformat: 1521-9437

ISSN Online: 1940-4344

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.2 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 1.4 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00066 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.34 SJR: 0.274 SNIP: 0.41 CiteScore™:: 2.8 H-Index: 37

Indexed in

The Development of the Antiviral Drug RC 28 from Rozites caperata (Pers.: Fr.) P. Karst. (Agaricomycetideae)

Volumen 7, Ausgabe 3, 2005, 356 pages
DOI: 10.1615/IntJMedMushrooms.v7.i3.180
Get accessDownload

ABSTRAKT

Many mushrooms are reported to have antiviral activity against viruses that cause human disease. The active substances described include polysaccharides, conjugated polysaccharides, proteins, peptides, lignins, triterpenes, phenoloic derivates, and nucleic acid bases. RC 28 is an antiviral protein of MW 28 kD prepared from aqueous extracts of the mushroom Rozites caperata with novel antiviral activity. It is active exclusively against enveloped viruses including human Herpes viruses HSV-1 and HSV-2, Cytomegalovirus, Varicella zoster, Respiratory syncytial virus, and Influenza Virus type A. It is not active against the non-enveloped viruses Adenovirus type 6, Coxsackie viruses B5 and B6, and several strains of ECHO viruses. Our present objectives are to obtain the complete amino acid sequence of RC 28, determine its antiviral mechanism, and identify its cellular targets. I will present some initial studies with these objectives in mind.
The antiviral effects of RC 28 were studied in Buffalo Green Monkey kidney cells (BGMK) and Hep-2 cells infected with the KOS strain of HSV-1 virus. The synthesis of viral proteins in BGMK cells was studied using Western blots of infected cell extracts from 4−12% PAGE gels stained with antibodies to HSV-1. Effects of RC 28 on the early functions of the HSV-1 immediate early protein, ICPO, and disaggregation of PML nuclear bodies was studied in Hep-2 cells stained with anti-ICPO antibodies and anti-PML antibodies. Localization and colocalization studies of RC 28 with cellular organelles were studied in Hep-2 cells stained with antibodies to RC 28, lysosomes, proteasomes, and ICPO. Cellular targets were studied using the Invitrogen Yeast Proto Array Slide Kit.
RC 28 interfered with the synthesis of viral structural proteins even when the drug was added as late as 13 hours after infection. RC 28 prevented the translocation of the HSV-1 immediate early protein, ICPO from the nucleus to the cytoplasm, and ICPO directed disaggregation of PML nuclear bodies. RC 28 localized exclusively in the cytoplasm but not in the nucleus of Hep-2 cells, and RC 28 did not colocalize with nuclear ICPO, cytoplasmic proteasomes, or lysosomes.
Presently, the drugs of choice for the treatment of Herpes virus infections are those that interfere with viral DNA replication—i.e., Acyclovir and second generation derivatives. RC 28 has unique and novel antiviral activities because it interferes with both early and late viral functions. It interferes with the functional activities of the immediate early protein ICPO and prevents the synthesis of late structural proteins even when RC 28 is added after viral DNA replication. Because of its unique antiviral activity, RC 28 may prevent infection by HSV-1 and HSV-2 Herpes viruses if the drug is applied within the first few hours following contact. It is to be hoped that the elucidation of the antiviral mechanism of RC 28 and the identification of its cellular targets will lead to the discovery of second generation RC 28-like drugs with even greater effectiveness, specificity, and usefulness for the treatment of Herpes virus infections.

REFERENZIERT VON
  1. Teplyakova T. V., Ilyicheva T. N., Markovich N. A., Prospects for the Development of Anti-Influenza Drugs Based on Medicinal Mushrooms (Review), Applied Biochemistry and Microbiology, 56, 5, 2020. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain